HPV-Related Throat Cancer Outcomes in Men Vary by Race, Ethnicity

By FYH News Team

Published on July 17, 2022

[ad_1]

FRIDAY, July 15, 2022 (HealthDay News) — Non-Hispanic white men are disproportionately affected by late-stage human papillomavirus (HPV)-related oropharyngeal cancer (OPC), but cancer-specific mortality (CSM) is increased among Hispanic and non-Hispanic black men , according to a study published online July 1 in the Annals of Cancer Epidemiology.

Seiichi Villalona, MD, of Rutgers Robert Wood Johnson Medical School in Piscataway, New Jersey, and colleagues examined age-adjusted incidence trends, late-stage diagnosis, survival, and CSM in men diagnosed with HPV-related OPC from 2005 to 2016 in the United States in a population-based retrospective cohort study.

The researchers found that 84.2 percent of the 162,183 HPV-related OPCs were in non-Hispanic white males; from 2005 to 2016, there was a 50 percent increase in the incidence of late-stage cancer among white males. Hispanic and non-Hispanic black men had similar late-stage diagnosis rates as white men, but they had a higher CSM (adjusted hazard ratio 1.17 and 1.79, respectively). The higher mortality among Hispanic and black men was reduced, but not eliminated, after adjustment for treatment.

“Since these oropharyngeal cancers are all potentially preventable through the administration of the HPV vaccine, public health campaigns are needed to increase awareness of HPV’s link to throat cancer, its signs and symptoms, and to increase the uptake of HPV vaccinations in all adolescents.” and young adults. men,” a co-author said in a statement.

Summary/Full Text

[ad_2]

Source link

Features

Download and distribute powerful vaccination QI resources for your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.